Rigel Pharmaceuticals Cash Flow Statement
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rigel Pharmaceuticals free cash flow
In fiscal 2025, Rigel Pharmaceuticals generated $75.7 million of operating cash flow. That left free cash flow of $75.7 million, a free-cash-flow margin of 25.7% of revenue. Free cash flow was up 140.4% from the prior year's $31.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Rigel Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 367.02M | 17.48M | -25.09M | -58.57M | -17.91M | -29.74M | -66.89M | -70.48M | -77.99M | -69.22M |
| Net Income growth (YoY) | +1999.08% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.42M | 2.23M | 1.24M | 998.00K | 1.16M | 706.00K | 683.00K | 594.00K | 465.00K | 941.00K |
| Stock-Based Compensation | 12.71M | 12.39M | 8.81M | 12.38M | 9.49M | 7.30M | 9.12M | 7.70M | 5.99M | 7.33M |
| Change in Working Capital | -24.06M | -12.55M | 10.41M | -29.71M | 1.88M | -34.53M | 9.94M | -521.00K | -3.14M | -9.33M |
| Operating Cash Flow | 75.66M | 31.47M | -5.74M | -73.76M | 5.88M | -52.19M | -41.51M | -58.83M | -77.56M | -75.89M |
| Capital Expenditures | — | — | — | -450.00K | -627.00K | -1.26M | -1.46M | -1.11M | -164.00K | -804.00K |
| Investing Cash Flow | -92.36M | 4.13M | -4.30M | 72.78M | -80.04M | 47.47M | -23.66M | 24.96M | -19.47M | 24.88M |
| Financing Cash Flow | 601.00K | -11.64M | 18.37M | 6.55M | 62.67M | 12.57M | 11.37M | 71.89M | 117.69M | 25.18M |
| Net Change in Cash | -16.11M | 23.96M | 8.33M | 5.57M | -11.48M | 7.85M | -53.80M | 38.03M | 20.66M | -25.82M |
| Free Cash Flow | 75.66M | 31.47M | -5.74M | -74.21M | 5.25M | -53.45M | -42.97M | -59.93M | -77.72M | -76.69M |
This table shows 10 annual periods of Rigel Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RIGL's reporting calendar. What is a cash flow statement?